Drugs / BR2021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06867497 | Feb → Oct 2025 overdue | pancreatic adenocarcinoma | Boryung Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR2021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06867497 ↗ |
| Route | Intravenous | “intravenous administration for 30 minutes” NCT06867497 ↗ |